Globant's AI Platform Cuts PharmaMar's Drug Discovery Time by 15x
Event summary
- Globant and PharmaMar launched a multi-agent AI system to accelerate oncology research, achieving 90% accuracy and 15x faster insights.
- The platform analyzes 4,500 research documents to prioritize 10 viable treatment-indication combinations from 8,000 possibilities.
- Over 20 specialized digital agents operate across preclinical, clinical, regulatory, commercial, and strategy areas.
- PharmaMar plans to extend capabilities to hypothesis generation, real-time compliance checks, and automated scientific reporting.
The big picture
Globant's collaboration with PharmaMar highlights the growing trend of AI integration in pharmaceutical R&D, aiming to reduce drug discovery timelines and improve decision-making accuracy. This partnership aligns with broader industry shifts towards digital transformation and AI-driven innovation in healthcare, potentially setting a new standard for oncology research.
What we're watching
- AI Adoption
- How Globant's AI platform will affect PharmaMar's R&D efficiency and drug development timelines.
- Regulatory Compliance
- Whether the AI system can sustain real-time compliance checks across global regulatory frameworks like FDA and EMA.
- Scalability
- The pace at which PharmaMar can extend AI capabilities to other areas like hypothesis generation and automated reporting.
Related topics